European Equities Traded in the US as American Depositary Receipts Fall in Monday Trading

MT Newswires Live
04 Feb

European equities traded in the US as American depositary receipts were lower late Monday morning, falling 1.0% to 1,351.08 on the S&P Europe Select ADR Index.

From continental Europe, the gainers were led by telecommunications company Nokia (NOK), which rose 0.8%, followed by accommodations booking company trivago (TRVG) and consumer goods giant Unilever (UL), which were up 0.7% and 0.3% respectively.

The decliners from continental Europe were led by biotech company Evaxion Biotech (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which fell 7.9% and 4.3% respectively. They were followed by medical device maker EDAP TMS (EDAP) and semiconductor company Sequans Communications (SQNS), which were down 4% and 3% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies Akari Therapeutics (AKTX) and Verona Pharma (VRNA), which increased 5.4% and 2.9% respectively. They were followed by pharmaceutical company Silence Therapeutics (SLN) and telecommunications operator Vodafone Group (VOD), which advanced 2.6% and 1.6% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company TC Biopharm (TCBP) and biotech company Trinity Biotech (TRIB), which lost 15% and 5.9% respectively. They were followed by biopharmaceutical company NuCana (NCNA) and software development company Endava (DAVA), shed 5.7% and 2.1% respectively.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10